Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
- Eisai Inc to Increase Belviq Sales Reps to 400 in US
October 17, 2013
- Toho Pharmaceutical’s Logistics Base TBC Sapporo Starts Operations: Toho Holdings
October 17, 2013
- NBI, Eli Lilly Submit NDA for SGLT-2 Inhibitor
October 17, 2013
- Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
- Otsuka Completes Acquisition of US Biotech Startup Astex
October 16, 2013
- Janssen, AZ to Copromote Prostate Cancer Treatment Abiraterone in Japan
October 16, 2013
- Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
- Santen Launches Preservative-Free Tapros Mini Ophthalmic Solution
October 15, 2013
- Kowa Files for Approval of Glaucoma Treatment K-115
October 15, 2013
- Otsuka, Lundbeck Initiate Multinational PIII Program of Novel AD Treatment Lu AE58054
October 15, 2013
- Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
- PAREXEL CEO Says Japan Will Remain as Important Market for CROs, Hopes Outsourcing Increases in Japan
October 11, 2013
- Ono to Set Up Local Subsidiary in South Korea, Eyeing Commercialization of Own Brands
October 11, 2013
- 36 Drug Makers Paid Approximately 400 Billion Yen to Doctors, Medical Institutions in FY2012; Mainly for R&D, But Also for Information
October 11, 2013
- 36 Drug Makers Spent 120 Billion Yen on Information Provision; Foreign-affiliated Companies Top Spending List
October 11, 2013
- DSP to Set Up New Anticancer Drug Sales Company in US, Eyes Launch of BBI608
October 10, 2013
- Kaketsuken Submits 1st Japan-Made Hemophilia Inhibitor Treatment for Approval
October 9, 2013
- Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea
October 9, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…